Immunoprecise Antibodies Stock Analysis

Immunoprecise Stock Analysis Notes

About 14.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.94. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immunoprecise Antibodies recorded a loss per share of 0.47. The entity last dividend was issued on the 23rd of November 2020. The firm had 1:5 split on the 23rd of November 2020. ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies is traded on NASDAQ Exchange in the United States. To learn more about Immunoprecise Antibodies call Jennifer Bath at 250-483-0308 or check out https://www.ipatherapeutics.com.

Immunoprecise Antibodies Investment Alerts

Immunoprecise Antibodies Upcoming and Recent Events

Immunoprecise Largest EPS Surprises

View All Earnings Estimates

Immunoprecise Stock Institutional Investors

Note, although Immunoprecise Antibodies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunoprecise Market Capitalization

The company currently falls under 'Micro-Cap' category with a total capitalization of 33.42 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunoprecise Antibodies's market, we take the total number of its shares issued and multiply it by Immunoprecise Antibodies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Immunoprecise Profitablity

The company has Net Profit Margin of (0.6) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.54) %, which entails that for every $100 of revenue, it lost $0.54.

Management Efficiency

Immunoprecise Antibodies has Return on Asset of (0.1099) % which means that on every $100 spent on assets, it lost $0.1099. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2572) %, meaning that it generated no profit with money invested by stockholders. Immunoprecise Antibodies' management efficiency ratios could be used to measure how well Immunoprecise Antibodies manages its routine affairs as well as how well it operates its assets and liabilities. At present, Immunoprecise Antibodies' Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.31, whereas Return On Tangible Assets are forecasted to decline to (1.42). At present, Immunoprecise Antibodies' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 73.7 M, whereas Non Currrent Assets Other are forecasted to decline to about 73.5 K.

Technical Drivers

As of the 19th of April, Immunoprecise Antibodies retains the Risk Adjusted Performance of (0.01), standard deviation of 5.93, and Market Risk Adjusted Performance of (0.08). Immunoprecise Antibodies technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Immunoprecise Antibodies, which can be compared to its competitors. Please check out Immunoprecise Antibodies variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Immunoprecise Antibodies is priced fairly, providing market reflects its last-minute price of 1.24 per share. Given that Immunoprecise Antibodies is a hitting penny stock territory we urge to closely look at its jensen alpha.

Immunoprecise Antibodies Price Movement Analysis

Immunoprecise Antibodies Predictive Daily Indicators

Immunoprecise Antibodies Forecast Models

Immunoprecise Antibodies' time-series forecasting models are one of many Immunoprecise Antibodies' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunoprecise Antibodies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunoprecise Antibodies prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunoprecise shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immunoprecise Antibodies. By using and applying Immunoprecise Stock analysis, traders can create a robust methodology for identifying Immunoprecise entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunoprecise analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunoprecise analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Immunoprecise Antibodies stock analysis indicators help investors evaluate how Immunoprecise Antibodies stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunoprecise Antibodies shares will generate the highest return on investment. By understating and applying Immunoprecise Antibodies stock analysis, traders can identify Immunoprecise Antibodies position entry and exit signals to maximize returns.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.

Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.